These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31778208)

  • 21. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
    Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
    Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents.
    Gemzell-Danielsson K; Buhling KJ; Dermout SM; Lukkari-Lax E; Montegriffo E; Apter D
    Contraception; 2016 Jun; 93(6):507-12. PubMed ID: 26872720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population.
    Fan G; Kang S; Ren M; Weisberg E; Lukkari-Lax E; Roth K; Shin S
    Contraception; 2017 Apr; 95(4):371-377. PubMed ID: 27913229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
    Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
    Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years.
    Nelson AL
    Expert Opin Drug Deliv; 2017 Sep; 14(9):1131-1140. PubMed ID: 28696796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of bacterial vaginosis, Trichomonas vaginalis and Candida albicans infection among new users of combined hormonal contraception vs LNG-IUS.
    Rezk M; Sayyed T; Masood A; Dawood R
    Eur J Contracept Reprod Health Care; 2017 Oct; 22(5):344-348. PubMed ID: 28849960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.
    Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Pukkala E
    Acta Oncol; 2016 Nov; 55(11):1281-1284. PubMed ID: 27148621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
    Bilgehan F; Dilbaz B; Karadag B; Deveci CD
    J Obstet Gynaecol Res; 2015 Sep; 41(9):1426-32. PubMed ID: 26180028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reactional changes in short-term levonorgestrel-releasing intrauterine system (lng-ius) use.
    Giraldo PC; Souza TC; Henrique GL; Monteiro I; Amaral R; Machado RB; Discacciati MG; Sanches JM
    Rev Assoc Med Bras (1992); 2019 Jul; 65(6):857-863. PubMed ID: 31340317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
    Nelson AL
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):833-842. PubMed ID: 28617060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
    Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
    Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs.
    Jensen JT; Reinecke I; Post TM; Lukkari-Lax E; Hofmann BM
    Contraception; 2023 Apr; 120():109954. PubMed ID: 36634730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
    Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
    J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
    Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
    Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
    Yela DA; Monteiro IM; Bahamondes LG; Del Castillo S; Bahamondes MV; Fernandes A
    Rev Assoc Med Bras (1992); 2006; 52(1):32-6. PubMed ID: 16622536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use.
    Darney PD; Stuart GS; Thomas MA; Cwiak C; Olariu A; Creinin MD
    Contraception; 2018 Mar; 97(3):210-214. PubMed ID: 29038072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The levonorgestrel intrauterine system: cohort study to assess satisfaction in a postpartum population in Kenya.
    Hubacher D; Masaba R; Manduku CK; Chen M; Veena V
    Contraception; 2015 Apr; 91(4):295-300. PubMed ID: 25601351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study.
    Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Joensuu H; Pukkala E
    Acta Oncol; 2016; 55(2):188-92. PubMed ID: 26243443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.